{
  "claim_id": "claim_000",
  "claim": "Flublok ensures identical antigenic match with WHO- and FDA-selected flu strains.",
  "document": "Zimmerman_et_al.__2023_",
  "verification_stats": {
    "total_extracted": 2,
    "verified": 0,
    "rejected": 2,
    "verification_rate": 0.0
  },
  "verified_evidence": [],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "RIV4 was Flublok.",
      "reason": "does not support claim",
      "original_explanation": "This quote explicitly identifies Flublok as the recombinant quadrivalent influenza vaccine (RIV4) evaluated in the study, establishing the product under discussion."
    },
    {
      "id": 2,
      "quote": "because it is not subject to mutations to the A (H3N2) glycosylation binding site that reduce the effectiveness of egg based vaccines.",
      "reason": "does not support claim",
      "original_explanation": "This statement directly supports the claim by indicating that Flublok (RIV4), unlike egg-based vaccines, is not affected by mutations that can occur during egg-based manufacturing, which can alter the antigenic match to WHO- and FDA-selected flu strains."
    }
  ],
  "model_used": "gpt-4.1"
}